Biobanks
Biobanks Market by Type (Disease-Oriented, Genomic-Based, Population-Based), Component (Consumables, Equipment, Services), Sample Type, Application, End User, Ownership - Global Forecast 2025-2030
SKU
MRR-437D4595886E
Region
Global
Publication Date
February 2025
Delivery
Immediate
2024
USD 115.43 billion
2025
USD 130.56 billion
2030
USD 246.72 billion
CAGR
13.49%

The Biobanks Market size was estimated at USD 115.43 billion in 2024 and expected to reach USD 130.56 billion in 2025, at a CAGR 13.49% to reach USD 246.72 billion by 2030.

Biobanks Market
To learn more about this report, request a free PDF copy

Biobanks are repositories that store biological samples, such as DNA, plasma, cells, and tissues, crucial for medical research and personalized medicine. Their definition encompasses a wide range of activities, from the collection and storage of samples to data management and distribution for research purposes. The necessity of biobanks stems from their potential to advance personalized medicine by enabling researchers to understand genetic and environmental health influences. They are vital for drug development and therapeutic advancements, providing applications in various fields, including genomics, stem cell research, and epidemiology. End-use scopes extend across academic institutions, hospitals, research organizations, and pharmaceutical companies, illustrating their widespread utility.

Key growth influencers for biobanks include technological advancements in cryopreservation and data analytics, the rising prevalence of chronic diseases, and increased funding for genomic research. Opportunities lie in integrating big data and AI to improve sample analysis and management, enhancing collaboration between stakeholders to streamline data sharing, and tapping into emerging markets where healthcare infrastructure is developing. Recommendations include investments in state-of-the-art storage technology and robust data security measures to safeguard sensitive information. However, challenges persist in biobanking, such as ethical considerations regarding consent and data privacy, high costs of infrastructure, and regulatory hurdles that can impede international cooperation.

Innovation areas ripe for exploration include the development of automated biobanking systems, improvements in biospecimen preservation methods, and advancements in digital health platforms that facilitate real-time data access. With the biobanking market characterized by a continuous evolution driven by research and development, businesses can benefit by focusing on strategic partnerships, investing in advanced biotechnologies, and prioritizing the establishment of ethical governance frameworks. Overall, while the market presents significant room for growth, companies must navigate logistical, legal, and ethical challenges to fully leverage the potential of biobanks in transforming healthcare and research paradigms.

Ask ResearchAI anything

World's First Innovative Al for Market Research

Ask your question about the Biobanks market, and ResearchAI will deliver precise answers.
How ResearchAI Enhances the Value of Your Research
ResearchAI-as-a-Service
Gain reliable, real-time access to a responsible AI platform tailored to meet all your research requirements.
24/7/365 Accessibility
Receive quick answers anytime, anywhere, so you’re always informed.
Maximize Research Value
Gain credits to improve your findings, complemented by comprehensive post-sales support.
Multi Language Support
Use the platform in your preferred language for a more comfortable experience.
Stay Competitive
Use AI insights to boost decision-making and join the research revolution at no extra cost.
Time and Effort Savings
Simplify your research process by reducing the waiting time for analyst interactions in traditional methods.

Market Dynamics

The market dynamics represent an ever-changing landscape of the Biobanks Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

  • Market Drivers
    • Growing demand for personalized medicine and genomics
    • Rapid expansion of precision medicine initiatives
    • Increasing investments in biobanking infrastructure development
  • Market Restraints
    • Stringent regulatory compliances on the development and international reach of biobanking
  • Market Opportunities
    • Advancements in technology enhancing efficiency of biobanking processes and data handling
    • Leveraging big data analytics in biobanks to enhance personalized healthcare outcomes
  • Market Challenges
    • Data privacy and security issues in biobanks

Market Segmentation Analysis

  • Type: Rising preference for population-based biobanks for facilitating longitudinal studies on disease progression and prevention strategies

    Disease-oriented biobanks are primarily leveraged by healthcare institutions and research laboratories focused on understanding pathogeneses and therapeutic interventions. Their growth is emphasized by the increasing prevalence of chronic conditions such as cancer and diabetes. Genomic-based biobanks find their core applications in personalized medicine, where major organizations utilize vast genomic datasets to identify genetic predispositions and develop targeted therapies. The burgeoning field of genomics, catalyzed by advancements such as Clustered regularly interspaced short palindromic repeats (CRISPR) and next-generation sequencing, ensures a robust trajectory for these repositories. Population-based biobanks cater to expansive epidemiological studies, providing invaluable resources for public health interventions and policy formulations. Their utility lies in representing diverse genetic, demographic, and health-related data sets that facilitate longitudinal studies on disease progression and prevention strategies. Recent developments in blockchain technology and secure data management enhance the credibility and reliability of these repositories, attracting substantial investments. Virtual biobanks, an emergent class gaining traction, leverage digital platforms to store and share biological data without the logistical constraints of physical sample handling. This type of biobanking addresses the storage scalability challenges and accelerates data integration across global research projects.

    Disease-oriented and genomic-based biobanks play a significant role in terms of funding and collaborations, whereas population-based and virtual types are gaining momentum by offering unique solutions to large-scale data aggregation and accessibility. Major manufacturers engage in strategic alliances to enhance biobanking infrastructure and streamline data interoperability. Moreover, commercialization strides are evident as companies implement biospecimen-derived product innovations for diagnostic purposes and therapeutic development. Emerging applications within these biobank types include the development of companion diagnostics from genomic datasets and the creation of precision public health strategies from population-based collections. Recent news highlights advances in digital biobanking platforms enabling remote access, which are crucial amid the ongoing digitization wave bolstered by the COVID-19 pandemic's paradigm shift in remote healthcare delivery. For instance, advancements in cloud-based data integration and analytics are accelerating collaborative research across borders, dissolving traditional biobanking barriers. Furthermore, evolving regulatory frameworks focusing on ethical data use and privacy, influenced by the European General Data Protection Regulation (GDPR), play a crucial role in shaping biobank operations across types.

  • Application: Expanding application of biobanks in clinical diagnostics for storing and accessing biological samples

    Clinical diagnostics harness biobanks primarily for storing and accessing biological samples that are critical for disease detection, making this category significant in diagnostic accuracy and precision medicine advancement. Personalized medicine leverages biobanks for its vast genetic resource databases, optimizing individualized treatment plans. With increasing emphasis on tailored healthcare, this sector is poised for expansive growth as biobanks provide crucial biological insights necessary for bespoke therapies. The research category remains a cornerstone, ensuring ongoing medical and scientific exploration. Biobanks serve as repositories that facilitate a continuum of basic and applied research, thereby accelerating innovation and discoveries in life sciences. Therapeutics, particularly broken down into drug development and gene editing, showcases the transformative potential of biobanks. Drug development benefits significantly from biobank resources for identifying biomarkers and validating therapeutic targets, whereas gene editing represents the frontiers of genetic manipulation technology, aided by precise biobank resources that streamline experimental efficacy and safety protocols.

    Major manufacturers are investing heavily in technology enhancements, particularly in automation and digital integration of biobank management systems, to address the growing demand for efficient sample tracking and data integration. Recent news highlights a surge in collaborative efforts among pharmaceutical giants and research institutions with biobanks, aiming to unlock the complexities of rare diseases and accelerate gene-editing innovations.

    Emerging applications in this sector are transformative, particularly the increasing integration of artificial intelligence and machine learning in analyzing vast biobank datasets, opening avenues for breakthroughs in predictive diagnostics and the expedited development of orphan drugs. Moreover, the rise of direct-to-consumer genomics services is indirectly fueling the biobanks market, as consumer-generated genetic data becomes integrated into larger research frameworks. The significance of biobanks as crucial assets in advancing cell-based therapies cannot be overstated either. From tissue regeneration to advanced therapeutic cloning, the interplay between stored biological samples and novel therapeutic techniques showcases a rich potential for future advancements. As ethical considerations and data security gain prominence, biobanks are adapting their strategies to enhance transparency and trustworthiness, further cementing their role as foundational pillars in the biomedical landscape.

Porter’s Five Forces Analysis

The porter's five forces analysis offers a simple and powerful tool for understanding, identifying, and analyzing the position, situation, and power of the businesses in the Biobanks Market. This model is helpful for companies to understand the strength of their current competitive position and the position they are considering repositioning into. With a clear understanding of where power lies, businesses can take advantage of a situation of strength, improve weaknesses, and avoid taking wrong steps. The tool identifies whether new products, services, or companies have the potential to be profitable. In addition, it can be very informative when used to understand the balance of power in exceptional use cases.

PESTLE Analysis

The PESTLE analysis offers a comprehensive tool for understanding and analyzing the external macro-environmental factors that impact businesses within the Biobanks Market. This framework examines Political, Economic, Social, Technological, Legal, and Environmental factors, providing companies with insights into how these elements influence their operations and strategic decisions. By using PESTLE analysis, businesses can identify potential opportunities and threats in the market, adapt to changes in the external environment, and make informed decisions that align with current and future conditions. This analysis helps companies anticipate shifts in regulation, consumer behavior, technology, and economic conditions, allowing them to better navigate risks and capitalize on emerging trends.

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Biobanks Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Biobanks Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Recent Developments

  • UK Biobank launches advanced proteomics study for disease research

    The UK Biobank's launch of an advanced proteomics study involves tracking 5,400 proteins across 600,000 samples, co-funded by 14 biopharmaceutical companies as part of the UK Biobank Pharma Proteomics Project. This initiative combines proteomic, genetic, and imaging data, offering unprecedented insights into disease mechanisms, diagnostics, and potential treatments. By analyzing protein levels over time from mid-to-late life, researchers can enhance disease prediction and drug discovery, with the first dataset available in 2026. [Published On: January 10, 2025]

  • ICMR's new diabetes biobank in Chennai for diabetes research and management in India

    The Indian Council of Medical Research (ICMR) has established India's first diabetes biobank in Chennai, in collaboration with the Madras Diabetes Research Foundation. This biobank aims to bolster diabetes research by collecting and storing biospecimens from national studies such as ICMR-INDIAB and the Registry of Youth-Onset Diabetes in India. It is anticipated to identify novel biomarkers, develop personalized treatment strategies, and support longitudinal studies. [Published On: December 15, 2024]

  • Strategic partnership between UK and Oxford Nanopore aims to advance genomics for enhanced healthcare and biosecurity

    The new partnership among UK Biobank, Genomics England, NHS England, and Oxford Nanopore aims to enhance UK healthcare through advanced genomics. By integrating Oxford Nanopore's cutting-edge sequencing technology, this partnership targets breakthroughs in cancer, genetic disease, and pandemic preparedness, notably through a biosurveillance system across NHS sites. [Published On: November 05, 2024]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Biobanks Market. This critical assessment involves a thorough analysis of the organization’s resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Biobanks Market, highlighting leading vendors and their innovative profiles. These include Acorn Biolabs, Inc., AMS Biotechnology (Europe) Limited, Artizan Biosciences, Inc., ASKION GmbH, Avantor, Inc., Bay Biosciences LLC, Beckman Coulter, Inc. by Danaher Corporation, Becton, Dickinson and Company, BioIVT LLC, BioKryo by L’AIR LIQUIDE S.A., BioLife Solutions Inc., BocaBio, Charles River Laboratories International, Inc., Cryoport Systems, LLC, CTIBiotech, Cureline, Inc., Firalis Group, Greiner AG, Hamilton Company, LVL Technologies GmbH & Co. KG, Merck KGaA, Micronic Holding B.V., ProteoGenex, Inc., Provia Laboratories, LLC, Qiagen N.V., Shanghai Outdo Biotech Co. Ltd, Taylor-Wharton, Tecan Trading AG, Thermo Fisher Scientific Inc., and UK Biobank Limited.

Market Segmentation & Coverage

This research report categorizes the Biobanks Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Disease-Oriented
    • Genomic-Based
    • Population-Based
    • Virtual
  • Component
    • Consumables
    • Equipment
      • Alarms & Monitoring Systems
      • Incubators & Centrifuges
      • Temperature Control Systems
    • Services
      • Data Management
      • Sample Analysis
      • Storage & Processing
      • Transpost
  • Sample Type
    • Blood Derivatives
    • Cell Lines
    • Nucleic Acid
    • Tissues
  • Application
    • Clinical Diagnostics
    • Personalized Medicine
    • Research
    • Therapeutics
      • Drug Development
      • Gene Editing
  • End User
    • Academic Institutions
    • Biotechnology Companies
    • Hospitals
    • Pharmaceutical Companies
  • Ownership
    • Academic Biobanks
    • Commercial Biobanks
    • Government Biobanks
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

This research report offers invaluable insights into various crucial aspects of the Biobanks Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?
Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Biobanks Market, by Type
  7. Biobanks Market, by Component
  8. Biobanks Market, by Sample Type
  9. Biobanks Market, by Application
  10. Biobanks Market, by End User
  11. Biobanks Market, by Ownership
  12. Americas Biobanks Market
  13. Asia-Pacific Biobanks Market
  14. Europe, Middle East & Africa Biobanks Market
  15. Competitive Landscape
  16. List of Figures [Total: 29]
  17. List of Tables [Total: 421 ]
  18. List of Companies Mentioned [Total: 30]
360iResearch Analyst Ketan Rohom
Download a Free PDF
Get a sneak peek into the valuable insights and in-depth analysis featured in our comprehensive biobanks market report. Download now to stay ahead in the industry! Need more tailored information? Ketan is here to help you find exactly what you need.
Frequently Asked Questions
  1. How big is the Biobanks Market?
    Ans. The Global Biobanks Market size was estimated at USD 115.43 billion in 2024 and expected to reach USD 130.56 billion in 2025.
  2. What is the Biobanks Market growth?
    Ans. The Global Biobanks Market to grow USD 246.72 billion by 2030, at a CAGR of 13.49%
  3. When do I get the report?
    Ans. Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
  4. In what format does this report get delivered to me?
    Ans. We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
  5. How long has 360iResearch been around?
    Ans. We are approaching our 7th anniversary in 2024!
  6. What if I have a question about your reports?
    Ans. Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
  7. Can I share this report with my team?
    Ans. Absolutely yes, with the purchase of additional user licenses.
  8. Can I use your research in my presentation?
    Ans. Absolutely yes, so long as the 360iResearch cited correctly.